Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting 2025

Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in compensated cirrhosis (F4c) due to MASH

Digital pathology reinforces fibrosis improvements observed through conventional pathology in the 96-week Phase 2b HARMONY trial

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced new findings from the SYMMETRY and HARMONY Phase 2b trials of efruxifermin in patients with compensated cirrhosis (F4c) due to metabolic dysfunction-associated steatohepatitis (MASH) and pre-cirrhotic (F2-F3) MASH, respectively. The data will be shared during two oral and two poster presentations at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025, taking place November 7-11, 2025, in Washington, D.C.

“Patients with cirrhosis due to MASH are at a high risk for hepatic decompensation and development of life-threatening complications. The results we are presenting at AASLD bolster our confidence in the potential of efruxifermin to provide a meaningful and differentiated therapeutic option for F4c and earlier stages of MASH,” said Kitty Yale, chief development officer of Akero Therapeutics. “Efruxifermin has consistently demonstrated clear antifibrotic activity in clinical trials. These new analyses provide further evidence of fibrosis reversal and reduced risk of disease progression with efruxifermin in patients with MASH, which is being validated in our ongoing Phase 3 clinical trial program.”

New post-hoc analyses of 96-week data from the SYMMETRY trial reinforce the antifibrotic activity of efruxifermin in F4c MASH:

• Efruxifermin was associated with statistically significant improvements in clinically significant portal hypertension (CSPH) risk, as assessed by Baveno criteria. CSPH, a serious complication of cirrhosis, increases risk of hepatic complications.
• Significantly more participants treated with efruxifermin vs. placebo met thresholds for clinically meaningful improvements in noninvasive measures of fibrosis that predict reduced risk of liver-related events.
• Evaluation of liver biopsies from SYMMETRY using AI-assisted digital pathology (HistoIndex) corroborated the fibrosis improvements previously demonstrated by conventional pathology and revealed that efruxifermin consistently reduced total fibrosis and septa area, key features of cirrhosis related to disease severity.